Dipexium Pharmaceuticals (Nasdaq: DPRX) and privately-held late stage pharma company PLx Pharma have announced a merger agreement.
The deal between the two US companies will see PLx Pharma merging with a wholly-owned subsidiary of Dipexium in an all stock transaction.
"This merger will provide PLx Pharma with the initial resources necessary to advance our contemplated development efforts for Aspertec"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze